MA-BIOGEN
Biogen (NASDAQ: BIIB) announced today the appointment of Catherine Steele as Senior Vice President of Corporate Affairs, effective July 17.
Ms. Steele, who brings more than 25 years of public affairs experience to Biogen, will lead the company’s corporate, product, and internal communications as well government affairs and patient advocacy efforts.
“Catherine is joining us at an exciting time in the evolution of Biogen,” said Chief Executive Officer Michel Vounatsos. “As we strengthen our pipeline, reaffirm our commitment to neuroscience and look to enter new therapeutic areas and markets globally, Catherine will play a crucial role in helping align our business with key public and patient audiences and establish Biogen with new stakeholders globally.”
Ms. Steele most recently served as Global Head, Communications and Patient Relations at Novartis Pharmaceuticals, where she was responsible for corporate reputation and helping drive external, internal and executive communication strategies. She also led the company’s social media and patient relations activities. Her career in the biopharma industry began at Roche, where she spent more than a decade in global communications and policy leadership roles.
"I am privileged to join Biogen, a respected and recognized pioneer in neuroscience," said Ms. Steele. "I look forward to building upon that legacy and being part of this company whose commitment to patients, families and society affected by neurological diseases is unwavering."
Ms. Steele holds dual undergraduate degrees in French and political science from the University of New Brunswick and a Master of Arts degree in political science from Carleton University.
About Biogen
Through cutting-edge science and medicine,
Biogen discovers, develops and delivers worldwide innovative therapies
for people living with serious neurological and neurodegenerative
diseases. Founded in 1978, Biogen is a pioneer in biotechnology, and
today the company has the leading portfolio of medicines to treat
multiple sclerosis; has introduced the first and only approved treatment
for spinal muscular atrophy; and is at the forefront of neurology
research for conditions including Alzheimer’s disease, Parkinson’s
disease and amyotrophic lateral sclerosis. Biogen also manufactures and
commercializes biosimilars of advanced biologics. For more information,
please visit www.biogen.com
.
Follow us on social media – Twitter
,
LinkedIn
,
Facebook
,
YouTube
.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170628005103/en/
Contact:
Biogen
MEDIA CONTACT:
Matt Fearer, +1 781-464 3260
public.affairs@biogen.com
or
INVESTOR
CONTACT:
Matt Calistri, +1-781-464-2442
IR@biogen.com
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
HIMSS24.4.2024 09:04:30 CEST | Press release
Digital Health Leaders Meet at HIMSS24 Europe to Deliver Solutions to Tomorrow’s Healthcare Challenges
SUZANO-VENTURES24.4.2024 09:02:29 CEST | Press release
Suzano Ventures invests up to US$5 million into Bioform Technologies to further develop bio-based plastic alternatives
KALRAY24.4.2024 09:02:29 CEST | Press release
Kalray Joins Arm Total Design, Extending Collaboration With Arm on Accelerated AI Processing
SES24.4.2024 08:51:26 CEST | Press release
SES’s O3b mPOWER System Starts Providing High-performance Connectivity Services
GALDERMA24.4.2024 07:01:35 CEST | Press release
Galderma Delivers a Strong Start to the Year With Record Net Sales of Over 1 Billion USD for the First Quarter and 12.4% Year-on-Year Growth
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom